BackPoniard Pharmaceuticals Overview

Poniard Pharmaceuticals Other Current Assets

Latest other current assets for PARD: $270K.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$268000.00
↓ 73.54% YoYΔ $-745000.00 vs prior year quarter

Peer average / median

Loading

Poniard Pharmaceuticals Other Current Assets History

Loading

Poniard Pharmaceuticals vs. peers: Other Current Assets Comparison

Loading

Poniard Pharmaceuticals Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Poniard Pharmaceuticals (PARD) FAQ

Poniard Pharmaceuticals's other current assets stands at $270K as of September 2011. That compares with $1M in the prior-year period — down 73.5% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Poniard Pharmaceuticals reported $270K in other current assets versus $1M a year earlier — a 73.5% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $1M in the prior-year period — down 73.5% year over year. Sustained growth in other current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Poniard Pharmaceuticals's other current assets evolved across reporting periods, while the comparison chart places PARD next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other current assets is commonly used to spot outliers. Poniard Pharmaceuticals's reading of $270K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.